Anna Dolnik
Overview
Explore the profile of Anna Dolnik including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
977
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Leppa A, Grimes K, Jeong H, Huang F, Andrades A, Waclawiczek A, et al.
Nat Genet
. 2024 Nov;
56(12):2790-2803.
PMID: 39587361
Chromosomal instability is a major driver of intratumoral heterogeneity (ITH), promoting tumor progression. In the present study, we combined structural variant discovery and nucleosome occupancy profiling with transcriptomic and immunophenotypic...
2.
Krumbholz M, Dolnik A, Strang E, Ghete T, Skambraks S, Hutter S, et al.
Mol Cancer
. 2024 Sep;
23(1):206.
PMID: 39327604
Chronic myeloid leukemia (CML) typically occurs in late adulthood. Pediatric CML is a rare form of leukemia. In all age groups, the characteristic genetic driver of the disease is the...
3.
Halik A, Tilgner M, Silva P, Estrada N, Altwasser R, Jahn E, et al.
J Hematol Oncol
. 2024 Aug;
17(1):70.
PMID: 39160538
Background: Deletions and partial losses of chromosome 7 (chr7) are frequent in acute myeloid leukemia (AML) and are linked to dismal outcome. However, the genomic landscape and prognostic impact of...
4.
Weichenhan D, Riedel A, Sollier E, Toprak U, Hey J, Breuer K, et al.
Blood Adv
. 2024 Aug;
8(19):5100-5111.
PMID: 39121370
Acute myeloid leukemia (AML) with the t(7;12)(q36;p13) translocation occurs only in very young children and has a poor clinical outcome. The expected oncofusion between break point partners (motor neuron and...
5.
Ramberger E, Sapozhnikova V, Ng Y, Dolnik A, Ziehm M, Popp O, et al.
Nat Cancer
. 2024 Jun;
5(8):1267-1284.
PMID: 38942927
Multiple myeloma (MM) is a plasma cell malignancy of the bone marrow. Despite therapeutic advances, MM remains incurable, and better risk stratification as well as new therapies are therefore highly...
6.
Klever M, Strang E, Hetzel S, Jungnitsch J, Dolnik A, Schopflin R, et al.
Blood Adv
. 2023 Aug;
7(21):6520-6531.
PMID: 37582288
Acute myeloid leukemia with complex karyotype (CK-AML) is associated with poor prognosis, which is only in part explained by underlying TP53 mutations. Especially in the presence of complex chromosomal rearrangements,...
7.
Donato E, Correia N, Andresen C, Karpova D, Wurth R, Klein C, et al.
Blood Adv
. 2022 Dec;
7(6):1011-1018.
PMID: 36453648
Acute myeloid leukemia (AML) is a heterogeneous disease characterized by high rate of relapse and mortality. Current chemotherapies whilst successful in eradicating blasts, are less effective in eliminating relapse-causing leukemic...
8.
Zhai Y, Singh P, Dolnik A, Brazda P, Atlasy N, Del Gaudio N, et al.
Mol Cancer
. 2022 Aug;
21(1):166.
PMID: 35986270
Background: Acute myeloid leukemia (AML) is a heterogeneous and aggressive blood cancer that results from diverse genetic aberrations in the hematopoietic stem or progenitor cells (HSPCs) leading to the expansion...
9.
Ng Y, Ramberger E, Bohl S, Dolnik A, Steinebach C, Conrad T, et al.
Nat Commun
. 2022 Feb;
13(1):1009.
PMID: 35197447
The immunomodulatory drugs (IMiDs) lenalidomide and pomalidomide are highly effective treatments for multiple myeloma. However, virtually all patients eventually relapse due to acquired drug resistance with resistance-causing genetic alterations being...
10.
Schnoeder T, Schwarzer A, Jayavelu A, Hsu C, Kirkpatrick J, Dohner K, et al.
Blood
. 2021 Oct;
139(7):1080-1097.
PMID: 34695195
In an effort to identify novel drugs targeting fusion-oncogene-induced acute myeloid leukemia (AML), we performed high-resolution proteomic analysis. In AML1-ETO (AE)-driven AML, we uncovered a deregulation of phospholipase C (PLC)...